Outset Medical Earnings Call Transcripts
Fiscal Year 2026
-
Operating at scale in acute and home dialysis markets, the company leverages innovative technology and a recurring revenue model to drive growth and improve patient outcomes. Strong financials, high retention rates, and a focus on gross margin expansion position it for continued market share gains and profitability.
Fiscal Year 2025
-
Revenue grew 5% in 2025 to $119.5M, with gross margin expansion and reduced cash burn. FDA clearance of the next-gen Tablo platform positions the company for further growth, with 2026 revenue guidance of $125M–$130M and continued margin improvement.
-
The organization has made significant operational and sales model improvements, resolving regulatory issues and enhancing recurring revenue streams. Q3 results missed expectations due to deal timing, but recurring revenue remains strong and margin improvement is on track. Leadership is confident in future growth and profitability.
-
Q3 revenue grew 3% year-over-year to $29.4M, but large enterprise deals shifted to Q4/2026, prompting a guidance cut to $115–$120M for 2025. Gross margin reached 39.9%, and cash use is projected to drop over 50% in 2025. Demand and pipeline remain strong.
-
Strong year-over-year growth is driven by a differentiated technology and a recurring revenue model, with significant progress in gross margin and operational efficiency. Acute and post-acute market penetration is accelerating, supported by a unique value proposition and robust sales transformation. Recurring revenue and acute care market strength are highlighted as underappreciated advantages.
-
Second quarter revenue grew 15% year-over-year to $31.4 million, driven by strong console sales and recurring revenue. Gross margin expanded to 38.4%, and full-year guidance was raised to $122–$126 million, reflecting confidence in commercial execution and market demand.
-
Acute and home dialysis markets are targeted with a technology-driven, cost-saving solution. Commercial transformation has led to broad-based revenue growth and improved pipeline management. Gross margin is on track to exceed 40% this year, with a long-term goal of 50%+ driven by recurring revenue and operational efficiency.
-
The meeting covered director elections, executive compensation, and amendments to equity plans, all of which were approved along with the auditor ratification. No shareholder questions were raised, and official results will be filed with the SEC.
-
Q1 marked a strong turnaround with revenue and margin growth, driven by a completed commercial transformation and robust demand. The company is focused on consistent execution, margin expansion, and leveraging a large U.S. market opportunity, with profitability targeted using existing cash resources.
-
Q1 revenue grew 6% year-over-year to $29.8M, with recurring revenue up 20% and console sales up 23% sequentially. Gross margin expanded to 37.6%, and operating loss was cut nearly in half. Guidance for 2025 remains conservative, with strong demand and profitability in sight.
-
The company is leveraging its Tablo technology to transform dialysis delivery, expanding in both acute and home markets with a focus on cost reduction, operational efficiency, and patient experience. Recent salesforce and process changes, along with a strengthened balance sheet, position it for renewed growth and margin expansion in 2025.
Fiscal Year 2024
-
Q4 revenue reached $29.5M, with strong recurring revenue and gross margin expansion, while operating expenses and net loss declined significantly. 2025 guidance targets 10% growth in installed base and recurring revenue, with continued margin improvement and reduced cash burn.
-
After overcoming regulatory and operational headwinds, the business has realigned its sales force, expanded its recurring revenue base, and improved gross margins. With strong customer adoption, a robust sales pipeline, and disciplined cost controls, it is positioned for growth and progress toward profitability in 2025.
-
Q3 2024 saw sequential revenue growth, record recurring revenue, and significant gross margin expansion, driven by strong adoption in acute, subacute, and home markets. Operating expenses and net loss declined, and full-year guidance was raised, with management expressing confidence in continued growth for 2025.
-
Q2 revenue fell short due to longer sales cycles and lower console sales, but recurring revenue and gross margin grew strongly. The company is restructuring its sales approach to target larger enterprise deals, expecting near-term disruption but maintaining a robust pipeline and strong long-term outlook.
-
TabloCart sales are ramping up after FDA clearance, with strong inventory and renewed customer engagement. Recurring revenues and cost reductions are driving improved margins and a faster path to profitability, while broad-based adoption in both acute and home markets continues.